199 related articles for article (PubMed ID: 32105718)
1. Solute carrier proteins and c-Myc: a strong connection in cancer progression.
Panda S; Banerjee N; Chatterjee S
Drug Discov Today; 2020 May; 25(5):891-900. PubMed ID: 32105718
[TBL] [Abstract][Full Text] [Related]
2. Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy.
Hushmandi K; Einollahi B; Saadat SH; Lee EHC; Farani MR; Okina E; Huh YS; Nabavi N; Salimimoghadam S; Kumar AP
Mol Metab; 2024 Jun; 84():101952. PubMed ID: 38705513
[TBL] [Abstract][Full Text] [Related]
3. A guide to plasma membrane solute carrier proteins.
Pizzagalli MD; Bensimon A; Superti-Furga G
FEBS J; 2021 May; 288(9):2784-2835. PubMed ID: 32810346
[TBL] [Abstract][Full Text] [Related]
4. Relevance of solute carrier family 5 transporter defects to inherited and acquired human disease.
Cannizzaro M; Jarošová J; De Paepe B
J Appl Genet; 2019 Nov; 60(3-4):305-317. PubMed ID: 31286439
[TBL] [Abstract][Full Text] [Related]
5. A phylogenetic analysis between humans and D. melanogaster: A repertoire of solute carriers in humans and flies.
Ceder MM; Fredriksson R
Gene; 2022 Jan; 809():146033. PubMed ID: 34673204
[TBL] [Abstract][Full Text] [Related]
6. Role of solute carrier transporters in regulating dendritic cell maturation and function.
Shao L; Yang M; Sun T; Xia H; Du D; Li X; Jie Z
Eur J Immunol; 2024 Feb; 54(2):e2350385. PubMed ID: 38073515
[TBL] [Abstract][Full Text] [Related]
7. Targeting SLC transporters: small molecules as modulators and therapeutic opportunities.
Schlessinger A; Zatorski N; Hutchinson K; Colas C
Trends Biochem Sci; 2023 Sep; 48(9):801-814. PubMed ID: 37355450
[TBL] [Abstract][Full Text] [Related]
8. Solute carrier transporters: emerging central players in tumour immunotherapy.
Chen R; Chen L
Trends Cell Biol; 2022 Mar; 32(3):186-201. PubMed ID: 34511324
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles of the solute carrier family in pancreatic cancer.
Wu Z; Xu J; Liang C; Meng Q; Hua J; Wang W; Zhang B; Liu J; Yu X; Shi S
Clin Transl Med; 2021 Mar; 11(3):e356. PubMed ID: 33783998
[TBL] [Abstract][Full Text] [Related]
10. Advances and Challenges in Rational Drug Design for SLCs.
Garibsingh RA; Schlessinger A
Trends Pharmacol Sci; 2019 Oct; 40(10):790-800. PubMed ID: 31519459
[TBL] [Abstract][Full Text] [Related]
11. Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers.
Bharadwaj R; Jaiswal S; Velarde de la Cruz EE; Thakare RP
Diseases; 2024 Mar; 12(3):. PubMed ID: 38534987
[TBL] [Abstract][Full Text] [Related]
12. Impact of Solute Carrier Transporters in Glioma Pathology: A Comprehensive Review.
Anagnostakis F; Kokkorakis M; Markouli M; Piperi C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298344
[TBL] [Abstract][Full Text] [Related]
13. The fruit fly Drosophila melanogaster as an innovative preclinical ADME model for solute carrier membrane transporters, with consequences for pharmacology and drug therapy.
Wang Y; Moussian B; Schaeffeler E; Schwab M; Nies AT
Drug Discov Today; 2018 Oct; 23(10):1746-1760. PubMed ID: 29890226
[TBL] [Abstract][Full Text] [Related]
14. Classification Systems of Secondary Active Transporters.
Perland E; Fredriksson R
Trends Pharmacol Sci; 2017 Mar; 38(3):305-315. PubMed ID: 27939446
[TBL] [Abstract][Full Text] [Related]
15. High-Throughput Expression and Purification of Human Solute Carriers for Structural and Biochemical Studies.
Raturi S; Li H; Chang YN; Scacioc A; Bohstedt T; Fernandez-Cid A; Evans A; Abrusci P; Balakrishnan A; Pascoa TC; He D; Chi G; Kaur Singh N; Ye M; Li A; Shrestha L; Wang D; Williams EP; Burgess-Brown NA; Dürr KL; Puetter V; Ingles-Prieto A; Sauer DB
J Vis Exp; 2023 Sep; (199):. PubMed ID: 37843272
[TBL] [Abstract][Full Text] [Related]
16. Welcome to the Family: Identification of the NAD
Ziegler M; Monné M; Nikiforov A; Agrimi G; Heiland I; Palmieri F
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34198503
[TBL] [Abstract][Full Text] [Related]
17. Solute carriers as drug targets: current use, clinical trials and prospective.
Rask-Andersen M; Masuram S; Fredriksson R; Schiöth HB
Mol Aspects Med; 2013; 34(2-3):702-10. PubMed ID: 23506903
[TBL] [Abstract][Full Text] [Related]
18. Targeting solute carriers to modulate receptor-ligand interactions.
Sijben HJ; Superti-Furga G; IJzerman AP; Heitman LH
Trends Pharmacol Sci; 2022 May; 43(5):358-361. PubMed ID: 35232590
[TBL] [Abstract][Full Text] [Related]
19. Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease.
Schumann T; König J; Henke C; Willmes DM; Bornstein SR; Jordan J; Fromm MF; Birkenfeld AL
Pharmacol Rev; 2020 Jan; 72(1):343-379. PubMed ID: 31882442
[TBL] [Abstract][Full Text] [Related]
20. Role of long non-coding RNAs and MYC interaction in cancer metastasis: A possible target for therapeutic intervention.
Fatma H; Siddique HR
Toxicol Appl Pharmacol; 2020 Jul; 399():115056. PubMed ID: 32445756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
